While revenue decline in Healthcare segment has continued to impact EBITDA margins, we like two points from Syrma’s Q1FY24 result: (1) Rest of the product portfolio has continued to report industry leading growth rates, (2) order book stands at INR 35bn at end of Q1FY24 (INR 30bn at end of Q4FY23) which indicates strong order intake for thecompany; we are also enthused as there is strong order inflow from existing as well as new customers.